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Oral Presentations S209milieu of GvHD includes IL-6, IL-12, and IL-23, favoring Th1/
Th17 differentiation over that of regulatory T cells (Treg). We
show that blockade of IL-6-receptor-alpha in vitro with tocilizumab
(humanized Mab, 5 ug/ml) fails to alter alloreactive T cell prolifera-
tion (P5NS, n5 4), Treg expansion (8.87 v 9.90%, P5NS, n5 4),
or Th1/Th17 differentiation (19 v 19.6%, 1.32 v 1.53%, P 5NS, n
5 3). Janus kinase 2 (JAK2) relays downstream signaling by IL-6, IL-
12, and IL-23, through the phosphorylation of signal transducer and
activator of transcription 3 (STAT3). We demonstrate that
TG101348, a very specific, small molecule inhibitor of JAK2,
when present during initial and secondary encounters between hu-
man T cells and fully HLA-disparate, allogeneic monocyte-derived
dendritic cells (moDCs), induces durable and specific T cell toler-
ance on reexposure to the priming alloantigens. TG101348 ablates
the IL-6/JAK2/pSTAT3 pathway in T cells (24 v 0%, P\0.05, n
5 5) without off-target effects on IL-2 or IL-15/JAK3/pSTAT5-de-
pendent signaling, which would interfere with Treg development
and important effector T-cell responses. JAK2 inhibition enhances
the ratio of CD4+ Tregs to CD8+CD25+ effector T cells in favor
of Tregs (Treg:Effector 1:2 vs 1:1, P\0.05, n 5 5). JAK2 inhibition
also reduces IL-6 (255 vs 157 pg/ml, P\0.05, n5 5) and TNF-alpha
(50 vs 15 pg/ml, P\0.05, n5 4) production in allogeneic MLRs, im-
pairing the activation of central and effector memory T cells, as well
as the expansion of responder Th1 (24 vs 14%, P\0.05, n 5 4) and
Th17 (2 vs 1%, P\0.05, n5 4). T cells primed by allogeneicmoDCs
have a profound inability to respond upon reexposure to fresh allo-
geneic moDCs from the original stimulator, whether the JAK2 in-
hibitor were present in either the primary or the secondary MLR
(P\0.05, n 5 4). This indicates that TG101348 can prevent initial
sensitization, as well as recall responses by already sensitized T cells,
to alloantigen. Responses to stimulation de novo by influenza matrix
peptide (fluMP), a pathogenic nominal antigen, remain intact (P 5
NS, n5 4). JAK2 inhibition, but not IL-6 blockade alone, therefore
induces durable tolerance in HLA-disparate pairings, without
broader immune impairment. These findings provide a strong ratio-
nale for exploring this strategy in both GvHD prophylaxis and treat-
ment.18
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Fanconi anemia(FA) is a rare disease characterized by progressive
bone marrow failure, congenital anomalies and striking predisposi-
tion to cancer. BMT is indicated for pts who develop pancytopenia,
myelodysplasia or acute leukemia. During the past 30 years we have
progressively decreased the dose of Cyclophosphamide(CY) in the
preparatory regimen which resulted in a significant increase in sur-
vival.
Objective: Analyze the outcome of 85 pts with FA submitted to an
HLA matched related BMT in 6 Brazilian centers using CY 60mg/
kg as the preparatory regimen.
Patient and Methods: Period: 07/1999-05/2011. Gender: 40F/
45M. Age 3-34 years (M: 9). Type of donor: Siblings:74pts; other re-
lated: 11pts. Eighty-two pts had severe pancytopenia while 3 had
overt myelodysplastic syndrome(MDS). All received the same prepa-
ratory regimen with CY60mg/kg and GVHD prophylaxis with cy-
closporin and methotrexate.
Results: 72 pts are alive between 5 months and 12 ys after BMT
(M:5ys) with an overall survival (OS) of 85% in 5 ys. Pts transplanted
under the age of 10(48pts) had an OS of 95,6% in 5ys. Two pts died
before D+28 and were not evaluable for engraftment. Rejection oc-
curred in 6 pts: 2 had primary graft failure and both are alive and well
after a 2nd BMT(same donor). Late graft failure occurred in 4 pts atamedian of 244 days after BMT(range: 152- 365 days). Three pts un-
derwent a 2nd BMT (same donor) and 2 are alive and well 8 and 10 ys
after transplant. All pts with overt MDS relapsed and died of pro-
gressive disease despite a 2nd BMT. Mucositis grade II-III occurred
in 80%. Seventeen of 81 evaluable pts developed Acute-GVHD
(grade III: 4pts, grade IV: 3pts) while 23/78 evaluable pts had
chronic-GVHD (extensive: 12 pts). In multivariate analysis, only
acute and chronic GVHD were associated with a lower OS. Four
pts developed carcinoma of the tongue between 2 and 5 years after
BMT, two are alive and one has active disease. All had extensive
C-GVHD involving the oral mucosa. Thirteen pts died between
12 and 2034 days after BMT (M: 256 days). The major causes of
death were related to GVHD/infections and rejection. TRM at
100 days was 6% and at 1 year was 10%.
Conclusions: This regimen is well tolerated and associated with an
excellent survival especially in children younger than 10 years. Acute
and chronic GVHD had an impact in overall survival and strategies
are being developed to reduce this complication.19
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Disease relapse remains a major obstacle to successful allogeneic
hematopoietic cell transplantation (HCT). The development of
chronic graft-versus-host disease (cGVHD) has been associated
with fewer relapses. However, the peak incidences of early relapse
and cGVHD commonly overlap after HCT and variations in treat-
ment make it difficult to evaluate the relative impact of cGVHD on
HCT outcomes. In this study, we investigated the association of
cGVHD and the incidence of late relapse (.12 months) after
HCT. The study included patients who were alive and disease free
at one year after HCT. We also assessed the impact of cGVHD
on treatment related mortality (TRM), disease free survival (DFS)
and overall survival (OS) for 1 year disease-free survivors. The study
included 7489 recipients of HCT from HLA-identical siblings or
URDs conditioned with high intensity regimens for acute myeloid
leukemia (AML), acute lymphoid leukemia (ALL), chronic myeloid
leukemia (CML), or myelodysplastic syndrome (MDS) between
1995 and 2004 and reported to the Center for International Blood
and Marrow Transplant Research. Forty-seven percent of the study
population was diagnosed with cGVHD within 12 months of HCT.
The protective effect of cGVHD on late relapse was limited to pa-
tients diagnosed with CML (RR: 0.47, 95% CI: 0.37-0.59,
P\0.0001). Other factors significantly associated with a lower risk
of relapse were early diagnosis of acute GVHD (within 29 days of
HCT), grafts from well-matched or partially-matched URD, and
GVHD prophylaxis other than T-cell depletion. cGVHD was sig-
nificantly associated with a higher risk of TRM (RR: 2.43, 95%
CI: 2.09-2.82, P\0.0001) and inferior OS (RR: 1.56, 95% CI:
1.41-1.73, P\ 0.0001). A separate analysis was performed for
CML patients to evaluate the impact of cGVHD specific variables
S210 Oral Presentationson outcomes. A lower risk of late relapse was seen with several
cGVHD specific variables (P\0.0001), i.e., mild, moderate or severe
cGVHD; de novo or progressive cGVHD; or involvement of any or-
gan with cGVHD. These results demonstrate a protective effect of
cGVHD on late relapse only in CML. In addition, presence of
cGVHD by 1 year after HCT was associated with a higher risk of
TRM and inferior OS in all patients (CML, AML, ALL, MDS).
Since the protective effect of cGVHD on late relapse was seen
only in CML patients, more aggressive measures to control cGVHD
may be beneficial especially in AML, ALL and MDS patients after
high intensity conditioning regimen.20
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Pre-clinical data showed that C3a priming of CD34+ HPC leads
to activation of CXCR4, improved migration towards an SDF1 gra-
dient, and faster hematopoietic recovery and better human engraft-
ment in mice. On the basis of these data, we hypothesized that
preincubation with C3a would be safe and enhance engraftment.
To test this hypothesis, we incubated the smaller of the two UCB
units with C3a 1 mcg/mL (Calbiochem, Gibbstown, NJ) for 30 min-
utes, and infused without washing. Ten patients, median age 62 (r:
30-68), 8 males, with AML (n 5 6), MDS (n 5 3) and Hodgkin’s
(n 5 1) were enrolled. Units were selected using the University of
Minnesota published criteria and all met lot release (endotoxin\5
EU/kg, negative gram stain, viability .45%). Conditioning con-
sisted of cyclophosphamide 50 mg/kg/x1day, fludarabine 40 mg/
m2/x5d, total body irradiation 200cGy/x1dwith antithymocyte glob-
ulin added in three since they had not had recent chemotherapy. Im-
munoprophylaxis consisted of cyclosporine A/mycophenolate
mofetil (MMF). The unmanipulated unit was infused first with the
C3a primed unit infused 30 min later. Patients were monitored for
24 h for evidence of infusional toxicities and activation of pathways
downstream of C3a by assessment of coagulation factors, IL-6,
TNF-alpha, histamine, tryptase and C-reactive protein before and
15, 30 and 60 min post-infusion. Grade 3 hypertension was the
only notable infusional toxicity in 5; no patient had demonstrable ac-
tivation of the complement pathway. Nine patients had neutrophil
recovery at a median of 9 days (range 6-26). On day 21, hematopoi-
esis was primarily derived from the C3a primed unit in 6 of 9 (67%)
evaluable patients and present but non-predominating in another.
While not expected to enhance the speed of neutrophil recovery after
a non myeloablative therapy where initial host recovery in expected,
these data suggest a potential repopulating advantage especially since
the C3a primed unit is smaller and infused last. Based on the safety
profile and potential impact on engraftment, a randomized phase
II clinical trial in the myeloablative setting where neutrophil recov-
ery rates are suboptimal (median 23 days) is being developed.21
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Iron overload is a common complication following hematopoietic
stem cell transplantation (HSCT), and recent evidence suggests that
it has an important influence on both morbidity and mortality. The
C282Y and H63D polymorphisms of the hemochromatosis gene
(HFE) are associated with increased iron absorption. We evaluated119 patients with CML in chronic phase (CML-CP) undergoing
myeloablative HSCT for the presence of HFE polymorphisms.
The frequency of polymorphismswas consistent with that of the nor-
mal population. The presence of the HFE polymorphisms was not
associated with ferritin levels pre or post-transplant and there was
no impact on OS, TRM, or relapse rate. Serum samples were avail-
able for 84 patients at regular intervals post-transplant.We evaluated
serum markers of iron overload and regulation including ferritin,
iron, transferrin saturation (%TSAT), Hepcidin-25, and growth dif-
ferentiation factor-15 (GDF-15) as well as markers of inflammation
such as CRP and interleukin-6 (IL-6).
We found significant associations between Hepcidin-25 levels (\
or.median of 119ng/ml) measured within 3months of HSCT (me-
dian 50.5 days) and 1-year OS (92.9% vs 69%, p5 0.002) and 1-year
TRM (7.6% vs. 29.2% P 5 0.04). The cause of death in all patients
was secondary to infection. There was no impact of Hepcidin-25 on
the occurrence/severity of GVHD (p5 0.64) or the incidence of re-
lapse (p5 0.13). Hepcidin-25 plays a pivotal role in iron metabolism
and its expression can be upregulated by iron overload as well as by
inflammatory stimuli such as IL-6. In keepingwith these findings, in-
creased levels of GDF-15, a member of the TGF-b family and reg-
ulator of Hepcidin-25, were also associated with increased TRM and
inferior 1-year OS (p 5 0.07 and p 5 0.021, respectively). In multi-
variate analysis, Gratwohl score (RR5 13.8, p5 0.001) and Hepci-
din-25 (RR 5 4.2 and p 5 0.027) were the only independent
predictors for 1-year OS. Our results suggest that post-transplant
Hepcidin-25 and GDF-15 levels may be useful biomarkers for pre-
dicting 1-year TRM andOS after HSCT. Larger prospective studies
are warranted to confirm our findings.22
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Background: Acute graft-vs.-host disease (GVHD) remains a major
source of morbidity andmortality after allogeneic hematopoietic cell
transplantation (HCT). CD30 is a cell surface membrane protein of
the tumor necrosis factor receptor family and is expressed on acti-
vated T-cells. We hypothesized that CD30 could be used as a bio-
marker of acute GVHD after allogeneic HCT.
Methods: Peripheral blood mononuclear cells were collected from
12 patients at the time of presentation of symptoms of acute
GVHD, but prior to the initiation of systemic corticosteroids. 15 pa-
tients without GVHD were used as controls (CONTROL). In the
GVHD group, sample collection ranged from day +23 to day +165
after HCT and was based on symptoms or signs suggestive of acute
GVHD. One patient developed GVHD following donor leukocyte
infusion (DLI). In the control group, sample collection ranged
from day +58 to +98 after HCT.
Results:There were no significant differences in baseline character-
istics between the two groups. Analysis by flow cytometry showed
that patients with acuteGVHDhad a higher percentage of CD30 ex-
pressing CD8+ T-cells: median 2.7% (range 0.5%-10.2%) in
GVHD vs. 0.4% (0.2%-3.2%) in CONTROL, (p\0.001). Further
immunophenotypical analysis showed that the difference was quite
pronounced in the effector memory subset (defined by
CD8+,CD45RO+,CD62L-): 3.4% (0.7%, 10.8%) GVHD vs 0.8%
(0.4%, 2.9%)CONTROL, (p5 0.003) and the central memory sub-
set (defined by CD8+,CD45RO+,CD62L+): median 15.6% (2.8%,
25.0%) GVHD vs. 2.3% (1.3%, 10.4%) CONTROL, (p\ 0.001).
There was no significant difference in CD30 expression in na€ıve cells
(CD8+,CD45RO-,CD62L+), CD4+ T-cell subsets, or regulatory
(CD127-,CD25+) T-cells. Time after HCT had no effect on expres-
sion of CD30.
Conclusions:These results suggest that CD30 expression on CD8+
T-cells after allogeneic HCTmay be a potential biomarker for acute
GVHD. More importantly, this study suggests that CD30 may rep-
resent a novel target for the therapy of acute GVHD after HCT.
Analysis with a larger number of samples is ongoing to confirm these
results.
